Chances of FDA approval for Spectrum Pharma's lung cancer candidate poziotinib and Oncopeptides' Pepaxto for multiple myeloma have taken a dive, after the regulator's expert advisors voted that ...

The FDA has issued a complete response letter (CRL) to Spectrum Pharma for poziotinib, its pan HER2 inhibitor for a form of lung cancer, according to South Korea's Hanmi Pharma, which originally ...

The approved product is therapeutically equivalent to Spectrum Pharmaceuticals Inc 's product. Fluorouracil injection is indicated for the treatment of patients with adenocarcinoma of the colon ...